The members of the Roivant Discovery scientific advisory board (SAB) are world-leading experts in quantum physics, computational drug development, parallel computing, biology and chemistry. Our SAB also includes clinicians whose insights into the needs of patients help guide the development of a new scientific paradigm and delivery of novel medicines for patients in need.
Scientific Advisors
-
Timothy P. Heffernan, Ph.D.
Head of Oncology Research, Division of Therapeutics Discovery & Development; Executive Director, Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, The University of Texas MD Anderson Cancer Center, Houston.
-
Sun Hur, Ph.D.
Oscar M. Schloss Professor, Department of Biological Chemistry and Molecular Pharmacology, Department of Pediatrics, Harvard Medical School
-
Pasi A. Jänne, M.D., Ph.D.
Thoracic medical oncologist at the Dana-Farber Cancer Institute; Professor at Harvard Medical School; Director of the Lowe Center for Thoracic Oncology; Director of the Belfer Center for Applied Cancer Science